MAOA gene hypomethylation in panic disorder - Reversibility of an epigenetic risk pattern by psychotherapy

Translational Psychiatry

Volumn 6, Issue , 2016, Pages

  Ziegler, C ^a   Richter, J ^b   Mahr, M ^a   Gajewska, A ^a   Schiele, M A ^a   Gehrmann, A ^a   Schmidt, B ^a   Lesch, K P ^a   Lang, T ^c,d   Helbig Lang, S ^e,f   Pauli, P ^a   Kircher, T ^g   Reif, A ^h   Rief, W ^g   Vossbeck Elsebusch, A N ⁱ   Arolt, V ⁱ   Wittchen, H U ^f   Hamm, A O ^b   Deckert, J ^a   Domschke, K ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c Christoph Dornier Foundation for Clinical Psychology   (Germany)

^d UNIVERSITY OF BREMEN   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h GOETHE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGORAPHOBIA; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DNA EXTRACTION; DNA METHYLATION; EPIGENETICS; FEMALE; GENE; GENETIC RISK; HUMAN; MAOA GENE; MARKER GENE; PANIC; PSYCHOTHERAPY; TREATMENT RESPONSE; CASE CONTROL STUDY; DNA SEQUENCE; GENETIC EPIGENESIS; GENETICS; PANIC DISORDER;

AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE A, HUMAN;

ADULT; CASE-CONTROL STUDIES; COGNITIVE THERAPY; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; MONOAMINE OXIDASE; PANIC DISORDER; SEQUENCE ANALYSIS, DNA;

EID: 84963700742     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.41     Document Type: Article

References (37)

1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655-679.
2. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158: 1568-1578.
3. Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry 2006; 11: 805-814.
4. Turecki G, Ota VK, Belangero SI, Jackowski A, Kaufman J. Early life adversity, genomic plasticity, and psychopathology. Lancet Psychiatry 2014; 1: 461-466.
5. Tiller JW, Bouwer C, Behnke K. Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. Int Clin Psychopharmacol 1997; 12: 27-30.
6. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999; 8: 621-624.
7. Reif A, Weber H, Domschke K, Klauke B, Baumann C, Jacob CP et al. Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations. Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 786-793.
8. Reif A, Richter J, Straube B, Hofler M, Lueken U, Gloster AT et al. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Mol Psychiatry 2014; 19: 122-128.
9. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13: 484-492.
10. Domschke K, Tidow N, Kuithan H, Schwarte K, Klauke B, Ambree O et al. Monoamine oxidase A gene DNA hypomethylation-a risk factor for panic disorder? Int J Neuropsychopharmacol 2012; 15: 1217-1228.
11. Wong CC, Caspi A, Williams B, Craig IW, Houts R, Ambler A et al. A longitudinal study of epigenetic variation in twins. Epigenetics 2010; 5: 516-526.
12. Stafford JM, Lattal KM. Is an epigenetic switch the key to persistent extinction? Neurobiol Learn Mem 2011; 96: 35-40.
13. Whittle N, Singewald N. HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand? Biochem Soc Trans 2014; 42: 569-581.
14. Philibert RA, Beach SR, Gunter TD, Brody GH, Madan A, Gerrard M. The effect of smoking on MAOA promoter methylation in DNA prepared from lymphoblasts and whole blood. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 619-628.
15. Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S, Fydrich T et al. Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 2011; 79: 406-420.
16. Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The mobility inventory for agoraphobia. Behav Res Ther 1985; 23: 35-44.
17. Domschke K, Tidow N, Schrempf M, Schwarte K, Klauke B, Reif A et al. Epigenetic signature of panic disorder: a role of glutamate decarboxylase 1 (GAD1) DNA hypomethylation? Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 189-196.
18. Ziegler C, Dannlowski U, Brauer D, Stevens S, Laeger I, Wittmann H et al. Oxytocin receptor gene methylation: converging multilevel evidence for a role in social anxiety. Neuropsychopharmacology 2015; 40: 1528-1538.
19. Domschke K, Tidow N, Schwarte K, Ziegler C, Lesch KP, Deckert J et al. Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response. J Neural Transm 2015; 122: 99-108.
20. Lewin J, Schmitt AO, Adorjan P, Hildmann T, Piepenbrock C. Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics 2004; 20: 3005-3012.
21. Domschke K, Tidow N, Schwarte K, Deckert J, Lesch KP, Arolt V et al. Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychopharmacol 2014; 17: 1167-1176.
22. Tadic A, Muller-Engling L, Schlicht KF, Kotsiari A, Dreimuller N, Kleinmann A et al. Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Mol Psychiatry 2014; 19: 281-283.
23. Unternaehrer E, Meyer AH, Burkhardt SC, Dempster E, Staehli S, Theill N et al. Childhood maternal care is associated with DNA methylation of the genes for brain-derived neurotrophic factor (BDNF) and oxytocin receptor (OXTR) in peripheral blood cells in adult men and women. Stress 2015; 18: 451-461.
24. Schuster R, Kleimann A, Rehme MK, Taschner L, Glahn A, Groh A et al. Elevated methylation and decreased serum concentrations of BDNF in patients in levomethadone compared with diamorphine maintenance treatment. Eur Arch Psychiatry Clin Neurosci; e-pub ahead of print 22 January 2016; doi: 10.1007/s00406- 016-0668-7.
25. Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry 1998; 155: 457-469.
26. Checknita D, Maussion G, Labonte B, Comai S, Tremblay RE, Vitaro F et al. Monoamine oxidase A gene promoter methylation and transcriptional downregulation in an offender population with antisocial personality disorder. Br J Psychiatry 2015; 206: 216-222.
27. Shumay E, Logan J, Volkow ND, Fowler JS. Evidence that the methylation state of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A enzyme in healthy men. Epigenetics 2012; 7: 1151-1160.
28. Karlsson H, Hirvonen J, Salminen J, Hietala J. Increased serotonin receptor 1A binding in major depressive disorder after psychotherapy, but not after SSRI pharmacotherapy, is related to improved social functioning capacity. Psychother Psychosom 2013; 82: 260-261.
29. Roberts S, Lester KJ, Hudson JL, Rapee RM, Creswell C, Cooper PJ et al. Serotonin tranporter methylation and response to cognitive behaviour therapy in children with anxiety disorders. Transl Psychiatry 2014; 4: e444.
30. Melas PA, Rogdaki M, Lennartsson A, Bjork K, Qi H, Witasp A et al. Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 2012; 15: 669-679.
31. Lopez JP, Mamdani F, Labonte B, Beaulieu MM, Yang JP, Berlim MT et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry 2013; 18: 398-399.
32. Perroud N, Salzmann A, Prada P, Nicastro R, Hoeppli ME, Furrer S et al. Response to psychotherapy in borderline personality disorder and methylation status of the BDNF gene. Transl Psychiatry 2013; 3: e207.
33. Yehuda R, Daskalakis NP, Desarnaud F, Makotkine I, Lehrner AL, Koch E et al. Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD. Front Psychiatry 2013; 4: 118.
34. Foa EB, Zoellner LA, Feeny NC, Hembree EA, Alvarez-Conrad J. Does imaginal exposure exacerbate PTSD symptoms? J Consult Clin Psychol 2002; 70: 1022-1028.
35. Nishith P, Resick PA, Griffin MG. Pattern of change in prolonged exposure and cognitive-processing therapy for female rape victims with posttraumatic stress disorder. J Consult Clin Psychol 2002; 70: 880-886.
36. Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 2009; 194: 483-490.
37. Cosci F, Knuts IJ, Abrams K, Griez EJ, Schruers KR. Cigarette smoking and panic: a critical review of the literature. J Clin Psychiatry 2010; 71: 606-615.